Agilent, PureHoney Partner to Develop New Applications for RapidFire/MS System
News Nov 01, 2016
Agilent Technologies and PureHoney Technologies announce a co-marketing agreement to develop new applications on the Agilent RapidFire 365 High-throughput Mass Spectrometry System.
Agilent acquired the RapidFire technology when it purchased BIOCIUS Life Sciences in 2011. PureHoney Technologies is a contract research organization founded in 2014 by the original developers of RapidFire MS instrumentation.
Agilent and PureHoney will work together to develop new applications for the Agilent RapidFire/MS System, and will independently create new workflows for pharma and biopharma research, as well as forensic toxicology and metabolomics analysis.
“Our partnership with PureHoney Technologies will enable both companies to synergistically enhance application offerings, providing scientists with a greater range of capabilities to enhance the depth and speed of pharmaceutical research,” said Monty Benefiel, Agilent vice president and general manager of the company’s Mass Spectrometry Division.
“Originally developed as a tool for label-free high-throughput screening over a decade ago, RapidFire/MS is now routinely used in applications ranging from ADME-Tox, proteomics metabolomics, clinical research to in vivo functional assays,” said Can Özbal, PureHoney Technologies president and CEO. “We are thrilled to be partnering with Agilent to develop the next generation of applications on this versatile platform.”
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.